Every morning: the new peptide trials, what the FDA and WADA changed, and one peptide broken down study by study, with human and animal data kept apart and every source linked.
Each issue runs the same four sections, so you know where to look for the part you care about.
When a GLP-1 or growth hormone trial reports, we give the placebo result, the dropout rate, how long it ran and, where it was measured, how much of the weight lost was muscle.
See the fat-loss trial chartExample: on July 23, 2026 an FDA advisory committee voted 8 to 6 to recommend adding BPC-157 to the list pharmacies may compound from. The vote does not bind the FDA, and it does not make BPC-157 legal to compound today.
Read the legal-status guideCell studies, then animals, then small human studies, then randomized trials. You see where the evidence stops, which for most research peptides is in rodents.
Browse the peptide databaseWe pull the paper a claim cites and report what it measured, in whom, and for how long. Often the paper studied something else.
How to read peptide researchA rat tendon study and a randomized human trial never share a sentence. Each finding is labeled with who or what it was tested in.
Links go to the trial paper, the FDA notice or the WADA list, not to other newsletters. You can check anything we say.
Every source linked so you can check it yourself.
A free account opens the dose tables from published trials and approved labels on every peptide page, lets you save peptides, and keeps a private log. Same email, no card.
Create a free account